Immunotherapy breakthrough: Pembrolizumab extends time to recurrence in aggressive bladder cancer Post author: Post published:January 27, 2024 Post category:uncategorized Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option. You Might Also Like At the hollow in Florida, the ‘medical freedom’ movement finds its base camp October 31, 2025 Study reveals MYC gene’s role in prostate cancer initiation and progression September 19, 2024 Explainable AI predicts ICU length of stay and guides clinical decision-making January 16, 2025